Allergan Aesthetics, an AbbVie company, announces the celebration of a milestone moment for Botox Cosmetic (onabotulinumtoxinA). April 15, 2022, will mark 20 years since the U.S. Food and Drug Administration (FDA) first approved the product to temporarily improve the look of moderate to severe glabellar lines, located between your eyebrows.1 It was the first product of its kind and has since received two additional aesthetic indications–in 2013 and 2017–making Botox Cosmetic the first and only neurotoxin that is FDA-approved for adults to temporarily improve the look of moderate to severe lines in three areas; frown lines, crow's feet and forehead lines.
"It has been remarkable to see how Botox Cosmetic has evolved in 20 years, one scientific study at a time that showcases the clinical significance of this treatment," said Dr. Jean Carruthers, MD, FRCSC, FRC (Poth). "Botox Cosmetic has not only changed the trajectory of my career but also the way the medical aesthetics community practices and teaches. By any account, two decades is a long time, however in medicine it is just the beginning, and I look forward to the next big milestone for Botox Cosmetic."
"This celebration is about reflecting on the people who helped make Botox Cosmetic a household name," said Carrie Strom, Senior Vice President, AbbVie, and President, Global Allergan Aesthetics. "We celebrate our customers, our colleagues and all the patients who have been a part of our success. We remain dedicated to Botox Cosmetic, the first product of its kind on the market. We are passionate about continuing to drive this market forward and our experienced team is working closely with healthcare providers to ensure we are delivering meaningful innovations that the market needs with our commitment to ongoing research."

Read more at PR Newswire >>